Pharmaceutical Market to Witness Huge Growth by key players Novartis, Lupin, Cipla, Cadila Healthcare


HTF Market Intelligence released a new research report of 89 pages on title ‘Impact of India on the Pharmaceutical Industry – Thematic Research’  with detailed analysis, forecast and strategies. The study covers key regions that includes North America, Europe, Asia-Pacific, South America, Middle East and Africa and important players such as Sun Pharma, Aurobindo, Dr. Reddy’s Laboratories, GlaxoSmithKline etc.

Request a sample report @

India has the third largest pharma market in the world by volume, after the US and China, driven by its strong manufacturing capabilities. It is the world’s top vaccine manufacturer and among the largest producers and exporters of active pharmaceutical ingredient (API) and generics globally. The country supplies over 60% of global vaccine demand, 40% of US generic demand, and 25% of all drugs in the UK. India has the third largest API industry globally, supplying 57% of APIs used by the World Health Organization (WHO) and its low-cost manufacturing of pharmaceuticals (about 33% lower than in western countries) continues to draw increasing foreign investment.

Approximately 97% of marketed products in India are generic and exports from India occupy 20% share by volume in the supply of generic medicines globally. Even though it is a leader in generics manufacturing, India lacks strong investment in the R&D of innovative drugs and needs to implement better-defined regulations to become more competitive in the biosimilars market. The Indian biosimilars market is currently limited but will likely see moderate growth over the next few years, with 15 biosimilars currently in development. There is currently less focus on the domestic development of innovative drugs, as the industry is focused on manufacturing.


– What industry, regulatory and technology trends define the Indian pharma market?
– Which deal types are the most prominent and shape India’s pharma industry?
– What is the outlook of clinical trials and pipeline products in India?
– Why is manufacturing the main focus of the pharma industry in India?

Key Highlights

– India has the third largest pharma market in the world by volume, after the US and China, driven by its strong manufacturing capabilities.
– India is a leader in generics manufacturing. Better-defined regulations are needed for India to become more competitive in the biosimilars market and more investment is needed in the R&D of innovative drugs.
– The top therapy areas among marketed and pipeline products in India are central nervous system (CNS) and infectious disease, respectively.

Buy this report @ USD1950


– Overview of marketed products including top therapy areas and indications, regulatory and market access details as well as company profiles.
– Key topics covered for India’s pharma market include trends, value chain, market analysis, opportunities, challenges and unmet needs and example deals.
– Pipeline and Clinical Trials analysis: Comprehensive data on emerging therapies under development by therapy areas, indications and companies as well as segmented by molecule type.
– Contract Manufacturing providing insightful review of the key manufacturing hubs in the country as well as of different types of services offered by contract development and manufacturing organizations (CDMO) in India.

Reasons to Buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential.
– Develop business strategies by understanding the trends shaping and driving the Indian pharma market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact India’s pharma market in the future.
– Design your development strategy through a review of potential novel targets or combinations across indications.
– Understand the challenges and strategies impacting the development of therapy agents in Indian preclinical studies and clinical trials.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the classes of therapies and indications that present maximum opportunities for consolidations, investments and strategic partnerships in India.

Companies Mentioned in the Report

Sun Pharma, Aurobindo, Dr. Reddy’s Laboratories, GlaxoSmithKline, Novartis, Lupin, Cipla, Cadila Healthcare, Micro Labs, IntraLabs India Pvt

Get Customization in the Report, Enquire Now @

Table of Contents
Executive Summary
Value Chain
Market Analysis
Clinical Trials
Marketed Products
Pipeline Products
Contract Manufacturing in India
Regulatory and Market Access
Market Drivers and Barriers
Contact Us


View Detailed Table of Content @

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
[email protected]
Ph: +1 (206) 317 1218

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts